Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Anti-IgE and other new immunomodulation-based therapies for allergic asthma Jonkers RE; van der Zee JSNeth J Med 2005[Apr]; 63 (4): 121-8Understanding of the cellular and molecular mechanisms in asthma has lead to the recognition of a number of potential therapeutic targets, a few of which have been evaluated in clinical studies. Parenteral administrations of both anti-IL-5 and IL-12 inhibit eosinophil recruitment to the airways, but display a lack of clinical efficacy. Interrupting the IL-4 pathway thus far has also shown disappointing results in clinical studies. Omalizumab is the first anti-IgE monoclonal antibody developed for the treatment of moderate to severe asthmatics to receive FDA approval. In a number of clinical trials treatment with omalizumab was associated with moderate improvements in a number of relevant endpoints, including the rate of occurrence of disease exacerbations. Newer DNA-based therapeutic strategies including DNA vaccination and the antisense oligonucleotides show promise but thus far have only been tested in animal models.|Anti-Allergic Agents/pharmacology/*therapeutic use[MESH]|Antibodies, Anti-Idiotypic/immunology/pharmacology/*therapeutic use[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/pharmacology/*therapeutic use[MESH]|Asthma/*drug therapy[MESH]|Drug Delivery Systems[MESH]|Humans[MESH]|Immunoglobulin E/*immunology[MESH]|Infusions, Parenteral[MESH]|Interleukin-12/pharmacology/therapeutic use[MESH]|Omalizumab[MESH]|Receptors, Interleukin-4/drug effects[MESH]|Receptors, Interleukin-5[MESH]|Receptors, Interleukin/drug effects[MESH] |